EuLDP project Manon van Hecke

Title: Cost-effectiveness of antiVEGF use in the Netherlands compared to different countries.

Introduction
In the Netherlands bevacizumab has been used as first-line treatment for macular vascular disorders like age-related macular degeneration, diabetic macula edema and macula edema with retinal venous occlusion, based on literature like CATT study results. When patients do not respond well to treatment with bevacizumab, guidelines advise to switch therapy to other more expensive antiVEGFs. However, because of extensive costs of ranibizumab and aflibercept, agreements have been made between hospitals and insurance companies on the percentage of usage of expensive antiVEGFs. More and more, this percentage is not sufficient for optimal treatment of the patients. This project reports on the use of antiVEGFs in the Netherlands, the costs and the benefits, in comparison to other European countries and the USA. Furthermore, issues concerning the ophthalmic budget as part of the total budget for expensive medication will be addressed.